Recent Advances in Epithelial Cells in Human Lung Disease
A special issue of Biomedicines (ISSN 2227-9059). This special issue belongs to the section "Cell Biology and Pathology".
Deadline for manuscript submissions: closed (30 November 2023) | Viewed by 2392
Special Issue Editors
Interests: cystic fibrosis; microRNA; induced pluripotent stem cell derived 3D organoid models; airway epithelial cell biology; Innate Immunity
Special Issue Information
Dear Colleagues,
Diverse cells of the airway epithelium play critical roles in response to injury, host defense, and the maintenance of homeostasis in the lung. When compromised, they also significantly contribute to human lung disease. Advances in cell biology over the last decade have yielded human in vitro research platforms derived from airway cells, and the epigenetic profiling of these models has the potential to discover key factors that regulate gene expression alterations in lung disease.
For example, human 3D organoid platforms have been demonstrated to be amenable to gene editing and personalized disease modelling, and transcriptomic analysis using single-cell RNA sequencing (scRNA-seq) has revealed substantial airway cell heterogeneity and uncovered previously unknown cell populations. Characterizing the role and function of existing and newly discovered epithelial cell populations is essential in order to provide clues to disease pathogenesis and treatment discovery.
This Special Issue aims to expand our understanding of complex molecular pathways within the airway epithelium in the pathophysiology of pulmonary diseases such as cystic fibrosis, pulmonary fibrosis, chronic obstructive pulmonary disease, and COVID-19 using personalized disease models and omics technology, as well as explore insights into novel therapeutics and drug delivery strategies.
Dr. Irene Oglesby
Dr. Chiara De Santi
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Biomedicines is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- pulmonary disease
- personalised disease modelling
- epithelial cells
- induced pluripotent stem cells
- transcriptomics
- epigenetics
- scRNA-seq
